RT Journal Article
SR Electronic
T1 Machine learning from the CARDAMON trial identifies a carfilzomib-specific mutational response signature
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.04.08.23288287
DO 10.1101/2023.04.08.23288287
A1 Ieuan G Walker
A1 Venetia D’arcy
A1 Garima Khandelwal
A1 Georgina Anderson
A1 Anna Aubareda
A1 William Wilson
A1 Evelyn Fitzsimons
A1 Daria Galas-Filipowicz
A1 Kane Foster
A1 Rakesh Popat
A1 Karthik Ramasamy
A1 Matthew Streetly
A1 Ceri Bygrave
A1 Reuben Benjamin
A1 Ruth M. de Tute
A1 Marquita Camilleri
A1 Selina J Chavda
A1 Gavin Pang
A1 Tushhar Dadaga
A1 Sumaiya Kamora
A1 James Cavenagh
A1 Elizabeth H. Phillips
A1 Laura Clifton-Hadley
A1 Roger G Owen
A1 Javier Herrero
A1 Kwee Yong
A1 Michael A Chapman
YR 2023
UL http://medrxiv.org/content/early/2023/04/09/2023.04.08.23288287.abstract
AB Precision medicine holds great promise to improve outcomes in cancer, including haematological malignancies. However, there are few biomarkers that influence choice of chemotherapy in clinical practice. In particular, multiple myeloma requires an individualized approach as there exist several active therapies, but little agreement on how and when they should be used and combined. We have previously shown that a transcriptomic signature can identify specific bortezomib- and lenalidomide-sensitivity. However, gene expression signatures are challenging to implement clinically. We reasoned that signatures based on the presence or absence of gene mutations would be more tractable in the clinical setting, though examples of such signatures are rare. We performed whole exome sequencing as part of the CARDAMON trial, which employed carfilzomib-based therapy. We applied advanced machine learning approaches to discover mutational patterns predictive of treatment outcome. The resulting model accurately predicted progression-free survival (PFS) both in CARDAMON patients and in an external validation set of patients from the CoMMpass study who had received carfilzomib. The signature was specific for carfilzomib therapy and was strongly driven by genes on chromosome 1p36. Importantly, patients predicted to be carfilzomib-sensitive had a longer PFS when treated with carfilzomib/lenalidomide/dexamethasone than with bortezomib/carfilzomib/dexamethasone. However, in those predicted to be carfilzomib-insensitive, the latter therapy may have been capable of eradicating carfilzomib-resistant clones. We propose that the signature can be used to make rational therapeutic decisions and could be incorporated into future clinical trials.Competing Interest StatementWalker: Abbvie & Janssen: Honoraria. Popat: Takeda: Research Funding; GSK: Honoraria, Research Funding; Janssen, Takeda, Celgene, and GSK: Honoraria; Janssen, Takeda, GSK: Other: Travel expenses from Janssen, Takeda GSK; Roche:Honoraria; BMS: Honoraria; Janssen: Honoraria; Takeda, AbbVie, GlaxoSmithKline, and Celgene: Consultancy. Benjamin:Bristol Myers Squibb/Celgene: Research Funding; Amgen: Research Funding. Clifton-Hadley: Astra Zeneca, GSK, Pfizer, MSD, BMS, Amgen, Millennium Takeda: Other: CRUK and UCL CTC have received research funding in the past 24 months, Research Funding. Owen: Astra Zeneca: Honoraria; Janssen: Honoraria Membership on an entity's Board of Directors or advisory committees; Beigene: Honoraria ;Membership on an entity's Board of Directors or advisory committees. Chapman:Sanofi: Honoraria.Clinical Protocols https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(22)00350-7/fulltext Funding StatementIGW is supported by the Kay Kendall Leukaemia Fund KKL1442 also received support from the UK Myeloma Society UKMS, VdA has received support from the UKMS. MAC is supported by the Medical Research Council Toxicology Unit MC UU 00025 10. KY and RP are supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. The Cardamon trial was funded by Amgen and endorsed by Cancer Research UK C9203 A17750.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The London City and East Research Ethics Committee London, UK gave full approval of study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. Data and code will be made publicly available on acceptance in a peer reviewed journal